6,6 BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3
Novel compounds of the structural Formula (I), and the pharmaceutically acceptable salts thereof are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be usefu...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
27.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Novel compounds of the structural Formula (I), and the pharmaceutically acceptable salts thereof are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease. Parkinson's Disease and traumatic brain injury.
De nouveaux composés de la formule développée (I) et leurs sels pharmaceutiquement acceptables sont des inhibiteurs de NLRP3, et peuvent être utiles dans le traitement, la prévention, la gestion, le soulagement, le contrôle et la suppression de maladies médiées par NLPR3. Les composés de la formule développée (I) peuvent être utiles dans le traitement, la prévention ou la gestion de maladies, de troubles et d'états médiés par NLRP3 tels que, mais sans s'y limiter, la goutte, la pseudo-goutte, le CAPS, la fibrose NASH, l'insuffisance cardiaque, la péricardite idiopathique, la dermatite atopique, la maladie intestinale inflammatoire, la maladie d'Alzheimer, la maladie de Parkinson et le traumatisme crânio-cérébral. |
---|---|
Bibliography: | Application Number: WO2023US83945 |